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Abstract
Purpose With the increased use of genetic testing for ar-
rhythmogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C), this disease is being increasingly recognised
among elderly patients. However, elderly ARVD/C pa-
tients were underrepresented in prior cohorts. We aimed
to describe the phenotypical characteristics and outcomes
among ARVD/C patients surviving ≥50 years.
Methods We assessed detailed phenotypical data of 29 pa-
tients who (1) presented at ≥50 years of age; and (2) ful-
filled 2010 Task Force Criteria (TFC) for ARVD/C by last
follow-up. Primary outcome was the occurrence of a major
ventricular arrhythmia (sudden cardiac death, resuscitated
sudden cardiac arrest or sustained ventricular tachycardia).
Results The majority (55 %) of elderly ARVD/C subjects
were male, with a mean age of 59.0 ± 5.8 years at pre-
sentation. Study participants fulfilled a median of six (IQR
5–8) TFC criteria by last follow-up, of which arrhythmia
criteria were most frequent (97 %), followed by structural
criteria (83 %), depolarisation criteria (72 %) and repolari-
sation criteria (69 %). By last follow-up, 15 (52 %) patients
had experienced major ventricular arrhythmias. Most pa-
tients (n = 12) presented with this arrhythmia, while three
experienced the event during 5.4 ± 3.2 years of follow-
up. Compared with patients without an arrhythmic event,
patients with major arrhythmias were more likely to be
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proband (p < 0.001) and male (p = 0.042). Likewise, sur-
vival free from sustained ventricular arrhythmia was lower
among probands and males.
Conclusion Phenotypic characteristics of elderly ARVD/C
patients are characterised by depolarisation abnormalities
and structural cardiac changes. Ventricular arrhythmias in
this elderly cohort are associated with male gender and
proband status.
Keywords Arrhythmogenic right ventricular dysplasia ·
Cardiomyopathy · Elderly · Ventricular arrhythmia ·
Clinical phenotype
Introduction
Arrhythmogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C) is an inherited cardiomyopathy characterised
by fibrofatty replacement of predominantly the right ven-
tricular myocardium, frequent ventricular arrhythmias, and
an increased risk of sudden cardiac death [1, 2]. ARVD/C
patients classically present between the second and fifth
decade of life with symptomatic ventricular arrhythmias
[3]. However, with increased use of molecular genetic
testing for ARVD/C, the disease is more frequently recog-
nised among elderly patients. Objective data describing
the phenotypic characteristics and clinical course of elderly
ARVD/C patients are currently lacking, which complicates
recommendations for the management of this growing
group of patients.
The objectives of this study were twofold. First, we
aimed to describe the phenotypical characteristics and clin-
ical course in a cohort of patients presenting with ARVD/C
at the age of 50 years or older. Second, we sought to
identify predictors of sustained ventricular arrhythmias that
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would be of value in determining which ARVD/C patients
would benefit from more intensive screening or prophylac-
tic implantation of an implantable cardioverter-defibrillator.
Methods
Study population
The study population was recruited from the University
Medical Center Utrecht ARVD/C registry [4]. We identified
29 patients enrolled in the registry who (1) presented for
first clinical evaluation at ≥50 years, and (2) were diagnosed
with definite ARVD/C in accordance with the 2010 Task
Fig. 1 Ascertainment of the
study population (UMCU Uni-
versity Medical Center Utrecht)
Force Criteria (TFC) by last follow-up [5]. Ascertainment
of the study population is shown in Fig. 1.
Clinical evaluation
Patients were evaluated as described previously [6]. Muta-
tion analysis of the desmosomal genes encoding plakophi-
lin-2 (PKP2), desmoplakin (DSP), desmoglein-2 (DSG2),
desmocollin-2 (DSC2), and plakoglobin (JUP), and the
non-desmosomal gene phospholamban (PLN) was per-
formed in all patients, as reported previously [6, 7]. Crite-
ria for pathogenicity of variants were determined as done
previously [4]. Twelve-lead electrocardiograms (ECGs)
(recorded at rest, 10 mm/mV at paper speed 25 mm/s) were
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evaluated for repolarisation (precordial T-wave inversion in
V1–2 or beyond) and/or depolarisation (epsilon waves or
terminal activation duration ≥55 ms) criteria for ARVD/C.
All patients were off drugs that influence ventricular depo-
larisation or repolarisation at the time of ECG recording.
Twenty-four hour Holter monitoring was used to determine
the frequency of premature ventricular complexes (PVC).
Exercise stress testing was performed to detect ventricular
tachycardia (VT) and ischaemia. Since signal-averaged
ECG was not available in this cohort, we used invasive
electrophysiological study as a measure of late potentials.
Electrophysiological studies were performed in 15 sub-
jects, the majority of whom (11/15, 73 %) had prior VT,
while the remainder (4/15, 27 %) were symptomatic and
had frequent ectopy on Holter monitoring. Late potentials
on electrophysiological study were defined as local elec-
trogram signals after termination of the QRS complex on
the surface ECG during sinus rhythm. Echocardiography,
cardiac magnetic resonance (CMR) imaging, and right ven-
tricular angiography were reviewed to determine cardiac
structural abnormalities. Per study design, all study par-
ticipants fulfilled diagnostic criteria for definite ARVD/C
according to the revised 2010 TFC [5].
Outcome
The primary outcome measure was the occurrence of a ma-
jor ventricular arrhythmia, which was a composite measure
of the occurrence of sudden cardiac death (SCD), resusci-
tated sudden cardiac arrest (SCA), or spontaneous sustained
VT (≥100/min, lasting ≥30 s or shorter with electrical or
pharmacological interruption), as done previously [8]. In
subjects with multiple endpoints, the first event was con-
sidered to be the censoring event.
Statistical analysis
Continuous data are displayed as mean ± standard devia-
tion or median (interquartile range [IQR]) and as propor-
tions for categorical variables. Differences in continuous
data were calculated using the independent samples t-test
or Mann-Whitney U test as appropriate; for categorical data
the Chi-square test or Fisher’s exact test was used. Kaplan-
Meier curves were calculated for time to an event of a ma-
jor ventricular arrhythmia. P-values <0.05 were considered
significant. Data were analysed using SPSS software (ver-
sion 22.0 for Mac).
Results
Study population
We included 29 patients who presented at ≥50 years of
age and were diagnosed with ARVD/C by last follow-up.
Their phenotypical characteristics are summarised in Ta-
ble 1. Overall, 16 (55 %) study participants were male,
with a mean age of 59.0 ± 5.8 years at the time of pre-
sentation. As shown in Fig. 2, the majority (n = 15, 52 %)
of patients presented between the age of 50 and 60 years.
ARVD/C-associated pathogenic mutations were found in 21
(72 %) patients; mutations were most frequently observed
in the plakophilin-2 (n = 14, 48 %) gene, while the remain-
der harboured a phospholamban mutation (n = 7, 24 %).
Table 1 Phenotypic characteristics of the study population




Age at presentation (years) 59.0 ± 5.8
Proband 16 (55)
Mutation carrier 21 (72)
Plakophilin-2 14 (48)
Phospholamban 7 (24)
Clinical phenotype at last follow-up
Age at diagnosis (years) 59.9 ± 6.7
Repolarisation TFC 20 (69)
T-wave inversion V1–3 16 (55)
T-wave inversion V1–2 2 (7)
T-wave inversion V4–6 2 (7)
T-wave inversion V1–4 with complete
RBBB
0 (0)
Depolarisation TFC 21 (72)
Epsilon wave 5 (17)
>TAD 17 (59)
Late potentials 8/18 (44)
Arrhythmia TFC 28 (97)
Holter abnormal 16/21 (76)
PVC count; median [IQR] 2056 [560–5952]
LBBB superior axis VT 13 (45)
LBBB VT 15 (52)
Structural TFC 24 (83)
Major 21 (73)
Minor 3 (10)
TFC points; median [IQR] 6 [5–8]
ARVD/C Arrhythmogenic right ventricular dysplasia/cardiomyopathy,
RBBB right bundle branch block, IQR interquartile range, LBBB left
bundle branch block, PVC premature ventricular complex,
>TAD prolonged terminal activation duration, TFC Task Force
Criteria, VT ventricular tachycardia
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Fig. 2 Age distribution of the study population. The distribution of
age at first clinical cardiac evaluation among the study population.
Overall, 28 % presented at 50–55 years, 24 % at 55–60 years, 21 %
at 60–65 years, 17 % at 65–70 years and 10 % at 70–80 years of age.
Mean age at time of presentation was 59.0 ± 5.8 (range 50.2–77.9)
years
Clinical evaluation
The majority (n = 23, 79 %) of patients fulfilled the diag-
nostic TFC at the time of first presentation; the remainder
(n = 6, 21 %) were diagnosed on average 3.6 ± 2.2 years
after presentation. Reasons for clinical presentation were
sustained monomorphic VT in 12 (41 %) patients, family
screening in 10 (34 %) patients, and syncope/presyncope or
palpitations in 7 (24 %) patients. No study subjects pre-
sented with an SCD or resuscitated SCA.
As shown in Table 1, T-wave inversions were observed
in 20 (69 %) elderly patients, most commonly (n = 16,
55 %) in leads V1–3. Depolarisation abnormalities were
observed in 21 (72 %) patients, of which terminal activation
duration ≥55 ms was the most frequent (n = 17, 59 %).
Twenty-four hour Holter monitoring showed >500 PVCs in
16/21 subjects (76 %). The majority of patients (n = 24,
83 %) had structural abnormalities on imaging studies. The
median TFC score was 6 (IQR 5–8) at last follow-up.
Ventricular arrhythmia
Among the overall population, 15 (52 %) patients experi-
enced a major ventricular arrhythmia, either at first pre-
sentation (n = 12, 80 %) or during follow-up (n = 3, 20 %).
All first major ventricular arrhythmias presented with spon-
taneous sustained VT. Clinical characteristics of these pa-
tients are shown in Table 2. Compared with subjects with-
out arrhythmia, patients who experienced an arrhythmic
event were more likely to be male (n = 11 [73 %] vs. n =
5 [36 %]; p = 0.042) and proband (n = 13 [87 %] vs. n = 3
[21 %]; p < 0.001). There were no other differences in de-
Fig. 3 Survival free from major ventricular arrhythmias among the
study population. Kaplan-Meier survival analyses demonstrating time
to first major ventricular arrhythmia during follow-up among the over-
all cohort
mographics or in any domain of the TFC between subjects
with and without arrhythmia.
In elderly patients, an obvious arrhythmic substrate may
occur in the setting of coronary artery disease (CAD). Elec-
trocardiographic evidence of previous myocardial infarction
was absent in all patients. In addition, we evaluated the
presence or absence of CAD using coronary angiography
and exercise stress testing in 15 patients with ventricular
arrhythmia. Two (13 %) of these patients had evidence
of CAD, defined as >50 % stenosis on coronary angiog-
raphy. The first subject presented at age 77 with left bundle
branch block (LBBB) inferior axis VT, and was found to
have a 70 % stenosis in the circumflex artery on coronary
angiography. CMR revealed right ventricular abnormali-
ties suggestive of ARVD/C, and further evaluation revealed
T-wave inversions in V1-4 and a radical mutation in the
plakophilin-2 gene (deletion exon 1–14). The second sub-
ject presented at 76 years of age with VT of LBBB superior
axis morphology and a normal left ventricular ejection frac-
tion of 54 %. However, a 70 % stenosis in margo obtusus 1
was found and subsequently treated with a bare metal stent.
The LBBB superior axis VT recurred, after which another
percutaneous coronary intervention was performed. After
several years of recurrent VT, a comprehensive follow-up
revealed ARVD/C based on late potentials, major structural
CMR abnormalities, and LBBB superior axis VT. All other
patients had no evidence of CAD on coronary angiography
(n = 11) and/or exercise stress testing (n = 14).
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Male 11(73) 5 (36) 0.042
Proband 13 (87) 3 (21) <0.001
Mutation carrier 10 (67) 11 (79) 0.682
Plakophilin-2 7 (47) 7 (50) 0.862






















Clinical phenotype at last follow-up
Age at diagnosis (years) 62.5 ± 9.7 60.9 ± 6.4 0.623
T-wave inversion V1–3 7 (47) 9 (64) 0.340
T-wave inversion V1–2 2 (13) 0 (0) 0.483
T-wave inversion V4–6 0 (0) 2 (14) 0.224
T-wave inversion V1–4 with complete RBBB 0 (0) 0 (0) –
Epsilon wave 4 (27) 1 (7) 0.330
>TAD 9 (60) 8 (57) 0.876
Late potentials 5/11 (45) 3/7 (43) 1.000
Holter monitor abnormal 5/8 (63) 11/13 (85) 0.325
PVC count; median [IQR] 919 [341–2095] 3108 [1205–6141] 0.205
Major structural TFC 13 (87) 8 (57) 0.109
Minor structural TFC 1 (7) 2 (14) 0.598
TFC points; median [IQR] 6[5–7] 6 [5–8] 0.506
RBBB right bundle branch block, IQR interquartile range, PVC premature ventricular complex, SCA sudden cardiac arrest, SCD sudden cardiac
death, >TAD prolonged terminal activation duration, TFC Task Force Criteria, VT ventricular tachycardia
Ventricular arrhythmia during follow-up
Fig. 3 shows cumulative survival free from major ventric-
ular arrhythmia in 17 patients who did not present with
an arrhythmia. Over a mean follow-up of 5.4 ± 3.2 years,
3/17 (18 %) patients experienced a sustained monomorphic
VT. Median cycle length of the VT was 240 ms (range
231–429). VT episodes showed LBBB morphology: two
with superior, one with inferior axis. As shown in Fig. 3,
median time to first VT was 4 months after first cardiolog-
ical evaluation. Cumulative survival free from major ven-
tricular arrhythmia after 6, 12 and 24 months was 88 %
(95 % CI 72.3–100.0), 88 % (95 % CI 72.3–100.0), and
80 % (95 % CI 60.4–99.6), respectively.
The characteristics of the three patients who experienced
an arrhythmic event during follow-up are shown in Table 3.
The first event was experienced at a median age of 59 (range
55–69) years. Interestingly, all patients with arrhythmia
were male and proband, and one of them was a carrier
of an ARVD/C-associated pathogenic mutation (plakophi-
lin-2). Prior to the arrhythmia, all three patients had re-
ported symptoms including exercise-induced syncope (n =
2), palpitations (n = 2), and/or presyncope (n = 1). At
the time of the arrhythmia, all patients fulfilled the TFC
for ARVD/C: repolarisation criteria were fulfilled in 1 pa-
tient (major), depolarisation criteria in 2 patients (1 major,
1 minor), and arrhythmia criteria in 3 patients (2 major,
1 minor) (Table 3). In addition, cardiac imaging showed
that all 3 subjects had major structural abnormalities. Dis-
tribution of age at diagnosis (p = 0.885), sex (p = 0.516)
and presence of a pathogenic mutation (p = 0.242) was sim-
ilar in patients with arrhythmic events at presentation and
during follow-up.
Discussion
This study has several interesting results. First, we found
that the clinical phenotype of elderly ARVD/C patients is
characterised by depolarisation abnormalities on 12-lead
ECG, frequent PVCs on Holter monitoring, and structural
alterations. Molecular genetic testing revealed a high per-
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Table 3 Characteristics of three patients experiencing first VT episode during follow-up
Patient #1 Patient #2 Patient #3
Demographics
Sex M M M
Age at time of diagnosis (years) 55 69 59
Proband Yes Yes Yes
Pathogenic mutation – – + (PKP2)
Sustained arrhythmia characteristics
Age at time of arrhythmia 55 71 59
Morphology LBBB LBBB LBBB
Axis Superior Superior Inferior
Cycle length (ms) 240 231 429
Documentation Walking Cardiac stress test Holter monitoring
Clinical phenotype at time of sustained arrhythmia
Repolarisation TFC None None TWI V1–4 (major)
Depolarisation TFC None Late potentials (minor) Epsilon wave (major)
Arrhythmia TFC LBBB superior axis VT (ma-
jor)
560 PVCs/24 h (minor),
LBBB superior axis VT
(major)
11180 PVCs/24 h (minor),
LBBB inferior axis VT (mi-
nor)
Structural TFC RV aneurysm + reduced RV
function (major)
RV aneurysm + reduced RV
function (major)
RV aneurysm + reduced RV
function (major)
Family history TFC None None Major
TFC points at time of arrhythmic event 4 5 8
Clinical features
Symptoms prior to event Exercise-induced syncope,
presyncope
Palpitations Palpitations
Medication at time of arrhythmia Perindopril 8 mg, Hy-
drochlorothiazide 25 mg
Atenolol 25 mg Acenocoumarola, Enalapril
20 mg, Simvastatin 40 mg
Relevant comorbidity Hypertension – Ischaemic CVA
Coronary angiography Normal Normal Normal
CVA cerebrovascular accident, LBBB left bundle branch block, PKP2 Plakophilin-2, PVC premature ventricular complex, TFC Task Force Criteria,
TWI T-wave inversion, VT ventricular tachycardia
a Indication for acenocoumarol was a history of ischaemic CVA
centage of phospholamban p.Arg14del mutation carriers.
Second, risk of SCD was low in this elderly cohort, since
none of the patients in this study experienced SCD/SCA.
Last, arrhythmic events in this elderly cohort were asso-
ciated with proband status and male gender, and all three
patients experiencing events during follow-up were male
and proband. These results provide interesting information
for clinical practice, which is still largely based on expert
opinion and consensus documents.
Clinical phenotype in elderly patients
Prior studies have extensively described phenotypical char-
acteristics in ARVD/C patients [3, 7, 9]. As such, we know
that depolarisation and repolarisation changes on 12-lead
ECG and frequent ectopy on Holter monitoring are often
observed in ARVD/C patients [3, 7, 8]. However, it is im-
portant to note that elderly patients were underrepresented
in prior ARVD/C cohorts, which typically had a mean age
between 20–40 years [3, 7, 9]. To the best of our knowl-
edge, the present study is the first to specifically focus on
those ARVD/C patients who only come to clinical atten-
tion after the age of 50 years. As in younger ARVD/C
subjects, ECG abnormalities, frequent ventricular ectopy,
and structural alterations are commonly observed in this
elderly cohort.
It is important to recognise that ventricular arrhythmias
in the elderly population have a broad differential diagno-
sis and CAD, in particular, is much more prevalent than
ARVD/C. Even in the 76-year-old patient in our ARVD/C
cohort, monomorphic VT was initially thought to be re-
lated to the 70 % stenosis in a coronary artery. However,
monomorphic VT in CAD in the absence of a previous my-
ocardial infarction is very rare. Although our study was not
designed to compare the clinical characteristics of elderly
subjects with and without ARVD/C, these results provide
a cautionary note to cardiologists, who may wrongly dis-
regard the diagnosis of ARVD/C based on older age at
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presentation. On the other hand, wall motion abnormalities
of the right ventricle are common and cardiologists should
be aware that non-pathological right ventricular wall mo-
tion disorders can easily be mistaken for a pathological
regional wall motion contraction, particularly in patients
with ARVD/C [10]. Future studies should address specific
treatment recommendations with regard to coronary artery
disease and its prevention among ARVD/C patients.
Genotype of elderly ARVD/C subjects
The yield of molecular genetic testing in ARVD/C typi-
cally lies between 50–63 % [7]. Our yield of 72 % is higher
than in previously published reports. This may be due to
a founder effect of the phospholamban p.Arg14del muta-
tion [11], which was observed in a remarkably large subset
of our population (24 %). Prior reports have shown that
ARVD/C patients who harbour a phospholamban mutation
present at an older age, frequently with left ventricular in-
volvement [12, 13]. In this regard, it is interesting that
only 62 % of our population had T-wave inversion in the
right precordial leads, in contrast to >85 % in the ARVD/C
literature [3, 7, 8]. This may reflect a left predominant
phenotype dominated by phospholamban mutations in our
population.
Elderly patients have a low risk of SCD
Prevention of SCD is the most important therapeutic goal in
ARVD/C [14]. Therefore, it is an important finding of our
study that none of the elderly patients in our cohort experi-
enced SCD/SCA either at presentation or during follow-up.
This is in contrast to prior studies with young ARVD/C pa-
tients which reported a 3–22 % rate of SCD [3, 4, 7]. This
finding is particularly interesting in the context of recent
basic science studies showing that desmosomal mutations
lead to reduced sodium current which promotes re-entry
susceptibility at an early disease stage [15–17]. In contrast,
heterogeneous fibrofatty replacement of the myocardium
leads to monomorphic sustained VT that is haemodynami-
cally stable and can be adequately treated. In our study pop-
ulation, 82 % already had structural abnormalities on car-
diac imaging. As such, we believe that our study subjects
were more likely to experience haemodynamically well-
tolerated monomorphic VT, rather than ventricular fibril-
lation. Future studies are necessary to determine whether
a true difference in arrhythmic substrate exists in younger
vs. elderly ARVD/C subjects.
Clinical characteristics in subjects with VT
Despite a low risk of SCD, malignant ventricular arrhyth-
mias are not uncommon among elderly ARVD/C patients.
Our study shows that more than half of ARVD/C patients
who present beyond 50 years of age experience a ventricular
arrhythmia during more than five years of follow-up. Al-
most all of these events occurred at presentation. As such,
the risk of ventricular arrhythmias seems highest for as yet
unrecognised cases. Ventricular arrhythmias were signifi-
cantly associated with male gender and proband status, and
arrhythmic events during follow-up occurred exclusively
among male probands. These data suggest that further
screening and invasive risk stratification in elderly ARVD/C
subjects may be most beneficial among male probands.
Study limitations
This study was limited by its small sample size. However,
this is consistent with a low prevalence of ARVD/C, possi-
bly due to under-recognition. Since this is a registry-based
study, not all subjects underwent all clinically available tests
such as Holter monitoring. It is possible that Holter mon-
itoring was mainly employed in those with mild disease,
which may explain a relatively modest PVC count in this
cohort. Data on exercise participation were not available.
Given recent studies confirming the role of strenuous ex-
ercise in phenotypic development of ARVD/C [18, 19], it
would be interesting to further investigate exercise partic-
ipation in elderly ARVD/C subjects. Detailed analysis of
the relationship between structural phenotype and age were
beyond the scope of this study. Since a large proportion
of elderly patients presented with ventricular arrhythmias,
only cross-sectional analyses could be performed to deter-
mine predictors of arrhythmic events. While we are aware
of the broad differential diagnosis of arrhythmias in an el-
derly population (particularly ischaemic heart disease), we
were unable to obtain coronary angiography in all patients.
Of note, all patients who did not undergo coronary angiog-
raphy had no electrocardiographic (exercise stress testing
or resting ECG) and CMR evidence of previous myocar-
dial infarction.
Conclusions
The results of our study show that ARVD/C in elderly pa-
tients is characterised by depolarisation abnormalities, fre-
quent ectopy on Holter monitoring, and structural changes
on cardiac imaging, while molecular genetic analysis re-
veals a high percentage of carriers of the phospholamban
p.Arg14del mutation. Ventricular arrhythmias are typically
haemodynamically well-tolerated monomorphic VT and are
associated with male sex and proband status. These results
suggest that further evaluation and more aggressive risk
stratification may be justifiable in male probands surviv-
ing beyond 50 years of age. Concomitant CAD remains
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a source of misinterpretation in the aetiology of monomor-
phic VT in this elderly age group.
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